Initial Findings on the Use of [<sup>225</sup>Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors.

Demirci, Emre; Alan Selçuk, Nalan; Beydagi, Gamze; Ocak, Meltem; Toklu, Türkay; Akçay, Kaan; Kabasakal, Levent

Initial Findings on the Use of [²²⁵Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors.

Demirci, Emre; Alan Selçuk, Nalan; Beydagi, Gamze; Ocak, Meltem; Toklu, Türkay; Akçay, Kaan; Kabasakal, Levent.

Afiliación

Demirci E; University of Missouri, Department of Radiology, Columbia, Missouri, USA.
Alan Selçuk N; Yeditepe University Faculty of Medicine, Department of Nuclear Medicine, Istanbul, Türkiye.
Beydagi G; Yeditepe University Faculty of Medicine, Department of Nuclear Medicine, Istanbul, Türkiye.
Ocak M; University of Missouri, Molecular Imaging and Theranostics Center, Columbia, Missouri, USA.
Toklu T; Yeditepe University Faculty of Medicine, Department of Nuclear Medicine, Istanbul, Türkiye.
Akçay K; Yeditepe University Faculty of Medicine, Department of Nuclear Medicine, Istanbul, Türkiye.
Kabasakal L; Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, Türkiye.

Mol Imaging Radionucl Ther ; 32(3): 226-232, 2023 Oct 20.

Article en En | MEDLINE | ID: mdl-37870290

Palabras clave

225Ac targeted alpha therapy; [225Ac]Ac-DOTATATE; neuroendocrine tumors; peptide receptor radionuclide therapy; theranostic

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Imaging Radionucl Ther Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google